Navigation Links
Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System
Date:1/28/2009

demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    CONTACTS:
    Paul Donovan
    Media Relations
    Boston Scientific Corporation
    508-650-8541 (office)
    508-667-5165 (mobile)

    Larry Neumann
    Investor Relations
    Boston Scientific Corporation
    508-650-8696 (office)


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor
2. Boston Scientific Acquires Labcoat Limited
3. FDA Approves Boston Scientifics Express(R) SD Renal Stent System
4. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
5. Boston Scientific to Participate in Piper Jaffray Health Care Conference
6. Trusted LASIK Surgeons Welcomes LASIK Expert Michael Raizman of Boston to its Unique LASIK Directory
7. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
8. FDA Approves Boston Scientifics Apex(TM) PTCA Dilatation Catheter
9. InterMune to Present at Deutsche Bank Biotech Boston Confab
10. Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability
11. Boston Scientific Announces Results for Third Quarter Ended September 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... New York (PRWEB) August 22, 2014 ... one of the interesting and challenging endeavors as ... renders highly impervious properties to the foreign substances. ... as possibility of self medication and minimal use ... low molecular weight drugs and provides specific targeting ...
(Date:8/22/2014)... Aug. 22, 2014 Research and Markets ... Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, ... report to their offering. The global ... in 2013, and is expected to grow at a ... Molecular biology enzymes, kits, & reagents find applications in ...
(Date:8/22/2014)... Canada (PRWEB) August 22, 2014 ... in model organisms can be accelerated by exome ... and manufacturing technologies, the custom SeqCap EZ Developer ... research. , Mr. Watson will additionally present how ... with commercially available human and mouse exome kits. ...
(Date:8/21/2014)... MD (PRWEB) August 21, 2014 DNA ... making progress in its development of JRC-LAMP-vax, an innovative ... cedar pollen. Phase IC studies began this month in ... to hay fever. , The Japanese red cedar releases ... people in Japan. Mountain Cedar pollen wreaks similar havoc ...
Breaking Biology Technology:Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 3Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4
... and GAITHERSBURG, Maryland, November 2, 2011 ... -based HPV Testing Increases Screening Coverage and is More ... Online in the Lancet Promising findings published ... a community-based, randomized equivalence trial undertaken by public health authorities ...
... announced that data from REMEDEE ( R andomized ... sirolimus coat ED bio- E ngineered ... Combo Bio-engineered Sirolimus Eluting Stent (Combo Dual Therapy Stent), will be ... Session at TCT 2011 in San Francisco. The presentation entitled "REMEDEE: ...
... Pharmaceuticals, Inc. (NASDAQ: OPTR ) today announced ... Credit Suisse Healthcare Conference on Thursday, November 10 at ... (Logo:   http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) A live ... the Investors page of the Company,s website at ...
Cached Biology Technology:Home-based Self-collected Vaginal Specimens Detect More Cervical Lesions and Cancers Than Cytology 2Home-based Self-collected Vaginal Specimens Detect More Cervical Lesions and Cancers Than Cytology 3Home-based Self-collected Vaginal Specimens Detect More Cervical Lesions and Cancers Than Cytology 4Home-based Self-collected Vaginal Specimens Detect More Cervical Lesions and Cancers Than Cytology 5Data From REMEDEE Trial Featuring OrbusNeich's Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011 2Data From REMEDEE Trial Featuring OrbusNeich's Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011 3
(Date:8/21/2014)... Conn. , Aug. 21, 2014 Nxt-ID, ... the growing mobile commerce market, announced today that its ... common stock to be issued in its proposed underwritten ... approved for listing on The Nasdaq Capital Market, subject ... the common stock and warrants, and will trade under ...
(Date:8/21/2014)... study aimed at improving the food intake, health and ... homes is among three projects at the University of ... the Canadian Institutes of Health Research (CIHR). , ... Sciences at Waterloo, and a Schlegel research chair in ... to investigate why many Canadians living in long-term care ...
(Date:8/21/2014)... , Saturday to Wednesday, Oct. 18-22, 2014 , ... W. Harbor Drive, San Diego, CA 92101 , ... and other presentations of the latest research in ... plenary session featuring high-scoring abstracts on rare genetic ... various cancers, and treatment for sun sensitivity (Saturday, ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2
... is available in Spanish . , The ... other forms of synaesthesia in which flavours are evoked ... time units, colours by music, etc. Experts on Experimental ... phenomenon. The results of this research have been published ...
... the ravages the disease can take on almost every ... addictive behaviors, even after a period of peaceable abstinence" ... brain active during decision making. "It,s perhaps ... that they have trouble thinking through a decision," said ...
... skates (skates made of animal bones) are the oldest ... BC. Why people started skating on ice and where ... in several locations spread across Central and North Europe. ... Journal of the Linnean Society of London, Dr Formenti ...
Cached Biology News:1 person out of every 1,000 has synaesthesia, in which an individual can smell a sound 21 person out of every 1,000 has synaesthesia, in which an individual can smell a sound 31 person out of every 1,000 has synaesthesia, in which an individual can smell a sound 4Cognitive, genetic clues identified in imaging study of alcohol addiction 2Cognitive, genetic clues identified in imaging study of alcohol addiction 3Cognitive, genetic clues identified in imaging study of alcohol addiction 4
...
Cag-A (IgG) -Ab EIA Sample Size: 10 l...
... Recombinant Ribonuclease Inhibitor is a ... ribonucleases such as RNase A. ... Recombinant Ribonuclease Inhibitor is an ... weight ~52 kDa. RNaseOUT inhibits ...
... Inhibitor (Ribonuclease inhibitor) is a ... to inhibit RNase activity. It ... endonuclease activity. , Inhibits ... RNA template , Lacks ...
Biology Products: